Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy, including CDK 4/6 inhibitors.

Read More

 | 12 Min. Read |  1

Capivasertib (Truqap) is a targeted therapy used to treat hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancers that test positive for certain gene mutations

Read More

 | 9 Min. Read |  1

Abemaciclib (Verzenio) is a targeted therapy approved by the Food and Drug Administration to treat hormone receptor-positive breast cancer.

Read More

 | 8 Min. Read |  2

HER2-positive or HER2-low breast cancer is caused by a genetic mutation in the HER2 gene. Learn more about the causes and treatment options for this type of breast cancer.

Read More

 | 14 Min. Read |  13

Trastuzumab (Herceptin) is the most common medicine used to treat HER2-positive breast cancer. It is a monoclonal antibody, a medicine made in a lab that attacks a specific protein produced on the outside of a cell.

Read More

 | 12 Min. Read |  1

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

Read More

 | 11 Min. Read |  8

Learn more about hormone receptor-positive metastatic breast cancer, which means the stage IV breast cancer is hormone-sensitive.

Read More

 | 6 Min. Read |  1

Hormone receptor-positive, or HR-positive, breast cancer grows in response to the hormones estrogen and progesterone. These hormones occur naturally in the body and prompt cell action in different ways.

Read More

 | 15 Min. Read |  5

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 6 Min. Read |  1

Palbociclib (Ibrance), a targeted therapy, was the first CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 5 Min. Read |  3